0001437749-21-013219.txt : 20210624 0001437749-21-013219.hdr.sgml : 20210624 20210525103305 ACCESSION NUMBER: 0001437749-21-013219 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REVIVA PHARMACEUTICALS HOLDINGS, INC. CENTRAL INDEX KEY: 0001742927 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 19925 STEVENS CREEK BLVD. STREET 2: SUITE 100 CITY: CUPERTINO STATE: CA ZIP: 95014 BUSINESS PHONE: 2127105220 MAIL ADDRESS: STREET 1: 19925 STEVENS CREEK BLVD. STREET 2: SUITE 100 CITY: CUPERTINO STATE: CA ZIP: 95014 FORMER COMPANY: FORMER CONFORMED NAME: Tenzing Acquisition Corp. DATE OF NAME CHANGE: 20180606 CORRESP 1 filename1.htm rvph20210523_corresp.htm

 

May 25, 2021

 

VIA EDGAR

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Attn:

David Gessert

 

 

Re:

Reviva Pharmaceuticals Holdings, Inc.

Registration Statement on Form S-1, as amended (File No. 333-255323)

 

 

Ladies and Gentlemen:

 

As the underwriter of the proposed offering of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time, on May 26, 2021, or as soon thereafter as is practicable. 

 

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

 

 

Very truly yours,
   
 

Maxim Group LLC
   
 

By: 

/s/ Clifford A. Teller              
   

Name: Clifford A. Teller
Title: Head of Investment Banking, Executive Managing Director